Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Targeting melanoma by small molecules: challenges ahead.

Haq R, Fisher DE.

Pigment Cell Melanoma Res. 2013 Jul;26(4):464-9. doi: 10.1111/pcmr.12109. Epub 2013 May 28. Review.

2.

Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts.

Wang W, Kim SH, El-Deiry WS.

Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):11003-8. Epub 2006 Jul 11.

3.

In vivo screening of S100B inhibitors for melanoma therapy.

Zimmer DB, Lapidus RG, Weber DJ.

Methods Mol Biol. 2013;963:303-17. doi: 10.1007/978-1-62703-230-8_18.

4.

Oral microparticulate vaccine for melanoma using M-cell targeting.

D'Souza B, Bhowmik T, Shashidharamurthy R, Oettinger C, Selvaraj P, D'Souza M.

J Drug Target. 2012 Feb;20(2):166-73. doi: 10.3109/1061186X.2011.622395. Epub 2011 Oct 10.

PMID:
21981679
5.

[Results of screening of antineoplastic agents: the eleventh report].

[No authors listed]

Gan To Kagaku Ryoho. 2007 Mar;34 Suppl 1:1-111. Japanese. No abstract available.

PMID:
17569278
6.

Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.

Stegmaier K, Wong JS, Ross KN, Chow KT, Peck D, Wright RD, Lessnick SL, Kung AL, Golub TR.

PLoS Med. 2007 Apr;4(4):e122.

7.

Synthesis of anti-microtubule N-(2-Arylindol-7-yl)benzenesulfonamide derivatives and their antitumor mechanisms.

Chiou CT, Chen GS, Chen ML, Li H, Shi L, Huang XH, Dai WM, Chern JW.

ChemMedChem. 2010 Sep 3;5(9):1489-97. doi: 10.1002/cmdc.201000228. No abstract available.

PMID:
20672297
8.

Antiproliferative activity of 2,3-disubstituted indoles toward apoptosis-resistant cancers cells.

Magedov IV, Lefranc F, Frolova LV, Banuls LM, Peretti AS, Rogelj S, Mathieu V, Kiss R, Kornienko A.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3277-82. doi: 10.1016/j.bmcl.2013.03.110. Epub 2013 Apr 8.

9.

Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.

Krayem M, Journe F, Wiedig M, Morandini R, Sales F, Awada A, Ghanem G.

Eur J Cancer. 2014 May;50(7):1310-20. doi: 10.1016/j.ejca.2014.01.021. Epub 2014 Feb 19.

PMID:
24559688
10.

Developing melanoma therapeutics: overview and update.

Korman JB, Fisher DE.

Wiley Interdiscip Rev Syst Biol Med. 2013 May-Jun;5(3):257-71. doi: 10.1002/wsbm.1210. Epub 2013 Feb 13. Review.

PMID:
23408545
11.

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes Foppen MH, Kemper K, Goding CR, McDermott U, Blank C, Haanen J, Graeber TG, Ribas A, Lo RS, Peeper DS.

Nat Commun. 2014 Dec 15;5:5712. doi: 10.1038/ncomms6712.

12.

Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.

Lee S, Shinji C, Ogura K, Shimizu M, Maeda S, Sato M, Yoshida M, Hashimoto Y, Miyachi H.

Bioorg Med Chem Lett. 2007 Sep 1;17(17):4895-900. Epub 2007 Jun 13.

PMID:
17588744
13.

In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.

Singh K, Munuganti RS, Leblanc E, Lin YL, Leung E, Lallous N, Butler M, Cherkasov A, Rennie PS.

Breast Cancer Res. 2015 Feb 25;17:27. doi: 10.1186/s13058-015-0529-8.

14.
15.

Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.

Fujita T, Mizukami T, Okawara T, Inoue K, Fujimori M.

Breast Cancer. 2014 Nov;21(6):738-47. doi: 10.1007/s12282-013-0452-8. Epub 2013 Mar 2.

PMID:
23456737
16.

The response of cancers to BRAF inhibition underscores the importance of cancer systems biology.

Stites EC.

Sci Signal. 2012 Oct 16;5(246):pe46. doi: 10.1126/scisignal.2003354.

PMID:
23074264
17.

BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.

Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Lizée G, Hwu P.

Clin Cancer Res. 2013 Jan 15;19(2):393-403. doi: 10.1158/1078-0432.CCR-12-1626. Epub 2012 Nov 30.

18.

Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design.

Yu W, Xiao H, Lin J, Li C.

J Med Chem. 2013 Jun 13;56(11):4402-12. doi: 10.1021/jm400080c. Epub 2013 May 16.

PMID:
23651330
19.

A cell-based screening to detect inhibitors of BRAF signaling pathway.

Asami Y, Mori M, Koshino H, Sekiyama Y, Teruya T, Simizu S, Usui T, Osada H.

J Antibiot (Tokyo). 2009 Feb;62(2):105-7. doi: 10.1038/ja.2008.17. Epub 2009 Jan 9. No abstract available.

PMID:
19132054
20.

Anti-tumor activities of peptides corresponding to conserved complementary determining regions from different immunoglobulins.

Figueiredo CR, Matsuo AL, Massaoka MH, Polonelli L, Travassos LR.

Peptides. 2014 Sep;59:14-9. doi: 10.1016/j.peptides.2014.06.007. Epub 2014 Jun 24.

PMID:
24972300

Supplemental Content

Support Center